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From previous data in animal models of cerebral ischemia, lipocalin-2 (LCN2), a protein
related to neutrophil function and cellular iron homeostasis, is supposed to have a value as
a biomarker in ischemic stroke patients. Therefore, we examined LCN2 expression in the
ischemic brain in an animal model and measured plasma levels of LCN2 in ischemic stroke
patients.
Methods
In the mouse model of transient middle cerebral artery occlusion (tMCAO), LCN2 expres-
sion in the brain was analyzed by immunohistochemistry and correlated to cellular nonheme
iron deposition up to 42 days after tMCAO. In human stroke patients, plasma levels of LCN2
were determined one week after ischemic stroke. In addition to established predictive
parameters such as age, National Institutes of Health Stroke Scale and thrombolytic ther-
apy, LCN2 was included into linear logistic regression modeling to predict clinical outcome
at 90 days after stroke.
Results
Immunohistochemistry revealed expression of LCN2 in the mouse brain already at one day
following tMCAO, and the amount of LCN2 subsequently increased with a maximum at 2
weeks after tMCAO. Accumulation of cellular nonheme iron was detectable one week post
tMCAO and continued to increase. In ischemic stroke patients, higher plasma levels of
LCN2 were associated with a worse clinical outcome at 90 days and with the occurrence of
post-stroke infections.
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Conclusions
LCN2 is expressed in the ischemic brain after temporary experimental ischemia and paral-
leled by the accumulation of cellular nonheme iron. Plasma levels of LCN2 measured in
patients one week after ischemic stroke contribute to the prediction of clinical outcome at 90
days and reflect the systemic response to post-stroke infections.
Introduction
Ischemic stroke is one of the leading causes of death and disability and utilises huge amount of
health care expenses [1]. Brain ischemia elicits systemic immunodepression that promotes
post-stroke infections. These occur in approximately one third of all stroke patients and impair
long-term recovery [2,3]. Lipocalin-2 (LCN2), also called neutrophil gelatinase-associated lipo-
calin or 24p3, is a crucial component of neutrophils [4–7] and expressed in a wide range of
hematogenous and non-hematogenous cells and tissues [8]. LCN2 participates in innate
immune responses, impacts on cell proliferation and differentiation [9], and regulates iron
homeostasis. Iron-loaded LCN2 enters cells via binding to the receptors 24p3R and LRP2/
megalin [10,11]. Iron-free LCN2 chelates intracellular iron and transfers it to the extracellular
space [10].
LCN2 has been established as a biomarker of acute kidney injury and a prognostic factor in
chronic kidney disease [12]. It was shown to be associated with mortality from cardiovascular
disease independent of traditional risk factors and kidney function [13]. Elevated circulating
levels were found in patients with transient ischemic attack and acute ischemic stroke [14]. In a
mixed cohort of ischemic and hemorrhagic stroke patients, raised LCN2 levels in the peripheral
blood obtained within 24 hours from symptom onset were associated with 6-month mortality
[15]. In animal models of peripheral lipopolysaccharide administration to induce a septic
inflammation, the protein was upregulated in choroidal epithelia, endothelial cells, astrocytes
and microglia [16,17]. In animal models of inflammatory brain injury [18–20], intracerebral
hemorrhage [21] and ischemic stroke [22,23], LCN2 upregulation occurred predominantly in
astrocytes and, to a lesser extent, in neurons. The significance of this finding is currently under
debate. Some authors conclude a role in promoting the migration of astrocytes, microglia and
neurons by induction of chemokine expression [24–26]. Others have proposed a relation of
LCN2 expression with the induction of astrogliosis and neuronal cell death [23,26,27]. These
conflicting results may be derived from different models and species used and different doses
of LCN2 applied in tissue experiments [28]. The expression of LCN2 in in vitro cultured glial
cells and in animal models has focussed attention to its putative use as a biomarker of CNS
injury including ischemic stroke [29]. In our study, we examined peripheral and central expres-
sion of LCN2 in a mouse model of transient middle cerebral artery occlusion (tMCAO). Fur-
thermore, plasma levels of LCN2 were measured in patients one week after ischemic stroke and
analyzed for a correlation to post-stroke infections and clinical outcome at 90 days.
Materials and Methods
Ethics statement
The study was approved by the institutional review board of the Medical University of Graz
(IRB00002556). Written informed consent was obtained from all participants. For patients
with impaired consciousness or aphasia, written informed consent was obtained when these
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patients regained the ability to communicate and were oriented to self and time. No surrogate
consent procedure was applied. Animal experiments were performed in accordance with the
European directive on the protection of animals used for scientific purposes and all other appli-
cable regulations and approved by the relevant authority, Landesamt fuer Gesundheit und
Soziales, Berlin, Germany.
Animal model of temporary middle cerebral artery occlusion (tMCAO)
Male SPF C57Bl6/J mice (Charles River Laboratories, Sulzfeld, Germany) were housed in cages
lined with chip bedding and environmental enrichment (mouse tunnel and igloo; Plexx B.V.,
Elst, The Netherlands) on a 12 h light/dark cycle (change 7 o’ clock) with ad libitum access to
food (standard chow) and water. At the time of the experiment, mice were 11–14 weeks old.
Cerebral ischemia was induced as described previously [30]. Briefly, a silicone coated filament
was introduced into the internal carotid artery, pushed forward to occlude the middle cerebral
artery at its origin and removed after 60 min. Isoflurane (Abott, Wiesbaden, Germany) in a 1:2
mixture oxygen/nitrous oxide was used for anaesthesia, and body temperature was maintained
throughout the whole procedure by a feedback controlled heating pad during the operation.
Animals were subsequently placed in heated cages (30°C) for a recovery period of 2 hours
before returning to their home cages. Animals were allowed free access to food and water.
Beginning one day prior to induction of cerebral ischemia until day 6 post tMCAO, mice
received preventive antibiotic treatment with marbofloxacin i.p. 5 mg/kg per day.
Ischemic lesion volumes were measured on day 1 after tMCAO by T2 weighted magnetic
resonance imaging on a 7T scanner (Pharmascan 70/16 AS, Bruker Biospin, Ettlingen, Ger-
many). Delineable hyperintense lesion volume was determined on 20 consecutive coronal slices
with 500μm thickness using Analyze 5.0 (AnalyzeDirect, Overland Park, KS, USA). Lesion vol-
ume was edema-corrected [31]. Mice with a lesion volume<25 mm2 were excluded from fur-
ther evaluation.
Animals were sacrificed on day 1 (n = 12), day 7 (n = 11), day 14 (n = 12), day 28 (n = 7)
and day 42 (n = 7) post tMCAO under high doses of ketamin/xylazin anaethesia by transcar-
dial perfusion with 4% paraformaldehyde (PFA). Brains were removed and postfixed in 4%
PFA for 24 hours. Paraffin embedded sections were examined by immunohistochemistry.
Ischemic lesions were delineated by reduced anti-MAP2 immunostaining as reported previ-
ously (abcam, Cat.-No. ab32454) [32]. Other primary antibodies were applied as follows: anti-
MAC3 (BD Biosciences, Cat.-No. 553322), anti-LCN2 (Sino Biological, Cat.-No. 50060-RP02),
anti-neuronal nuclei (NeuN; Millipore, Cat.-No. MAB377), anti-glial fibrillary acidic protein
(GFAP; Thermo Scientific, Fremont, CA; Cat.-No. MS-1376). Bound primary antibody was
detected with a biotin-avidin technique using 3,3’-diaminobenzidine-tetrahydrochloride
(DAB; Sigma, St. Louis; MO, USA) as chromogen. Control sections were incubated in the
absence of primary antibody. Double staining for LCN2/NeuN was performed with antibodies
from different species and detection by DAB and histogreen (Linaris, Wertheim, Germany).
Quantification of labeled cells in the striatum of ischemic hemispheres and respective contra-
lateral regions was performed by an ocular morphometric grid under a 200x objective. Values
were transformed to cells/mm2.
For ferrous nonheme iron, a DAB-enhanced Turnbull blue reaction procedure was applied
as described elsewhere [33]. Briefly, sections were deparaffinised and incubated in ammonium
sulphide 2% in distilled water (Merck, Darmstadt, Germany) for 90 min. After washing, sec-
tions were treated with an aqueous solution of 10% potassium ferricyanide (Merck, Darmstadt,
Germany) in 0.5% HCl. Endogenous peroxidase was blocked in methanol using 0.01 M sodium
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azide and 0.3% hydrogen peroxide for 1 h. Tissue iron was visualized by 20 min incubation in
0.025% DAB and 0.0005% hydrogen peroxide in 0.1 M PBS.
Serum was obtained from mice 7 days post tMCAO (n = 15) and from a group of naïve con-
trol mice (n = 11) and stored at -80°C for analysis. LCN2 levels in mouse serum were analyzed
by ELISA according to the manufacturer’s instructions (Kit 042; BioPorto Diagnostics, Gen-
tofte, Denmark).
Patients
Patients with a diagnosis of ischemic stroke according to clinical examination and brain imag-
ing (computerized tomography or magnetic resonance imaging) were eligible when they had a
National Institutes of Health Stroke Scale (NIHSS) of more than 3 on admission and a modi-
fied Rankin Scale (mRS) of 0 or 1 before symptom onset. The NIHSS was obtained on admis-
sion by board certified neurologists. The mRS was obtained 90 days post stroke by telephone
interviews with the patients or their caregivers [34]. Stroke was classified according to the
Oxfordshire Community Stroke Project (OCSP) [35] and the Causative Classification of Stroke
System (CCS) [36]. Patients were excluded from the study if their neurological symptoms per-
sisted for less than 24 hours and if there was already evidence for any infectious disease includ-
ing an abnormal leukocyte count on admission. Patients were not eligible when they had major
surgery or transfusion of blood components in a timeframe of 3 weeks prior to the stroke.
Further exclusion criteria were applied as follows: acute renal failure, chronic hemodialysis,
congestive heart failure NYHA III/IV, active malignancy, immunosuppressive treatment. Cere-
brovascular risk factors were identified as defined by preadmission history or the need for
medication at discharge: hypertension, hypercholesterolaemia, and diabetes mellitus. Atrial
fibrillation was diagnosed either by history, an electrocardiogram (ECG) on admission, or Hol-
ter-ECG during the hospital stay. None of the patients involved in the study suffered from a
myocardial infarction. Post-stroke infections were defined as infections which became evident
by clinical, radiological or laboratory means after the onset of acute stroke and required antibi-
otic treatment. No preventive antibiotics were given. Clinical care was performed according to
the guidelines of the European Stroke Organization. Venous blood was drawn at 8.00 a.m. one
week after acute stroke onset (median 7 days, range 5–9). Lithium-heparin plasma samples
were stored at -80°C for further analysis. LCN2 levels in patient plasma were analyzed by
ELISA according to the manufacturer’s instructions (Kit 036CE; BioPorto Diagnostics, Gen-
tofte, Denmark). C-reactive protein (CRP) levels and the estimated glomerular filtration rate
(eGFR), determined by the Modification of Diet in Renal Disease formula [37], were obtained
by standard laboratory procedures. One patient received atorvastatin at the time of blood sam-
pling which was previously shown to decrease plasma levels of LCN2 [38].
Statistical analysis
Student’s t-test, Mann-Whitney’s U-test, the Chi-square test or Fisher’s exact test, and Spear-
man’s rank order correlation were applied for two-group comparisons. The level of significance
was set at a p-value of less than 0.05. A stepwise linear logistic regression model was used for
analyzing variables to predict clinical outcome. Variables with p-values less than 0.1 were
included in an initial predictive model. Backwards elimination logistic regression was per-
formed to generate final predictive models. Receiver operator characteristic (ROC) curves were
constructed and discrimination of models was assessed by comparing areas under the curve
(AUC) with MedCalc1 11.6.1. software [39]. All other statistical analysis was performed by
IBM SPSS Statistics 20.
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Results
Animal model of temporary middle cerebral artery occlusion (tMCAO)
Ischemic brain lesions were delineated by a reduced MAP2 staining in the striatum and fre-
quently the neocortex in tMCAO mice (Fig 1). Prominent macrophage/microglia (MAC3)
immunoreactivity throughout ischemic lesions was found (Figs 1 and 2a). LCN2 was expressed
in cells with macrophage/microglia and astrocyte morphology in subacute and chronic ische-
mic lesions (Fig 2b). Single neurons in peri-infarct areas with LCN2-immunoreactivity 7 days
post tMCAO were identified by double immunostaining for LCN2/NeuN (Fig 2c). The number
of LCN2 expressing cells gradually increased from the first day post tMCAO with a maximum
two weeks later (Fig 3; S1 File). Notably, the amount of LCN2 positive cells gradually decreased
from that time-point until the end of the experiment (Fig 3; S1 File). No LCN2 positive cells
were found in non-ischemic hemispheres at all analyzed time-points. In ischemic hemispheres,
accumulation of cellular nonheme iron was detectable one week post tMCAO and continued
to increase. Highest cellular nonheme iron loads were found at day 28 post tMCAO (Fig 3, S1
File). In adjacent serial sections, nonheme iron staining co-localized with macrophage/micro-
glia but not with GFAP immunoreactivity (Fig 4). Serum levels of LCN2 in mice 7 days post
tMCAO showed no difference compared to controls (378.5 vs. 346.0 ng/ml; p = 0.72; S1 File).
Levels of LCN2 in mouse serum did not correspond to the volume of ischemic lesions (data
not shown).
Plasma levels of LCN2 in ischemic stroke patients and clinical outcome
Plasma samples were obtained from 46 consecutive patients at median of 7 days (range 5–9
days) after the onset of ischemic stroke. Demographics, clinical characteristics, cerebrovascular
risk factors and stroke classification of patients are given in Table 1.
Notably, plasma levels of LCN2 did not correlate with NIHSS upon admission (rS = 0.08;
p = 0.58). A correlation of LCN2 plasma levels with the mRS at 90 days after stroke was found
(rS = 0.40; p<0.01). For further analysis, patients were dichotomized into favourable (mRS
0–2) and unfavourable (mRS 3–6) outcomes 90 days after stroke. Median NIHSS, the propor-
tion of post-stroke infections and the proportion of total anterior circulation stroke (TACS)
differed significantly between these patient subgroups (Table 1). In contrast to patients with
mRS 0–2, those who had mRS 3–6 showed significantly higher median plasma levels of LCN2
measured one week after stroke (75.5 vs. 43.4 ng/ml; p = 0.03; Fig 5). 27 patients (58.7%) devel-
oped post-stroke infections: urinary tract infections (n = 17), pneumonia (n = 8), and other
(n = 2). Among patients with post-stroke infections, the median plasma level of LCN2 was
significantly higher as compared to patients with no infections (86.4 ng/ml vs. 43.4 ng/ml;
p = 0.006; Fig 5, S2 File). Plasma LCN2 levels did not correlate with maximum CRP levels mea-
sured one week after stroke (rS = 0.23; p = 0.12). Notably, CRP levels provided no prognostic
information for clinical outcome 90 days post stroke (data not shown). Furthermore, no differ-
ence in LCN2 levels was found between patients with or without hypertension (data not
shown). LCN2 plasma levels in our study are in the range of levels found previously in patients
with acute ischemic or hemorrhagic stroke [14,15]. To our knowledge, there is no previous
data about LCN2 levels measured one week after stroke onset as done in our study.
The relevance of LCN2 plasma levels to predict an unfavorable vs. favorable clinical out-
come was evaluated by comparing predictive models. Model 1 included NIHSS, patients’ age,
thrombolytic therapy and the estimated glomerular filtration rate (eGFR). The eGFR as a mea-
sure of chronic kidney disease is an independent predictor of poor outcome and long-term
mortality in patients with stroke [40]. Previously, LCN2 was reported to negatively correlate
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with the eGFR [38] which was also found in our study (rS = -0.321; p = 0.030). Predictive
model 2 further included LCN2 (Table 2). The addition of LCN2 to the established prediction
parameters significantly increased the AUC of generated ROC curves from 0.851 (model 1) to
0.935 (model 2), thereby demonstrating the value of LCN2 plasma levels measured one week
after stroke for predicting clinical outcome at 90 days.
Discussion
Our study is the first to describe long-term expression kinetics of LCN2 in tMCAO, an animal
model of ischemic stroke. The presence of LCN2 in rat tMCAO and postmortem human ische-
mic brain was previously reported up to 3 days post stroke [22,41]. We could demonstrate
a continuous presence of LCN2 in the ischemic mouse brain expressed predominantly by
Fig 1. Immunohistochemistry in the mouse brain at days 1, 7, 14, 28 and 42 after temporal middle
cerebral artery occlusion. Reduced MAP2 immunostaining delineates ischemic lesions (left column).
Macrophage/microglia infiltration is shown by MAC3 immunostaining (right column).
doi:10.1371/journal.pone.0154797.g001
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Fig 2. Immunohistochemistry in the mouse brain after temporal middle cerebral artery occlusion
(tMCAO).Macrophage/microglia infiltration (anti-MAC3, brown, a) and lipocalin-2 (LCN2) expression in cells
with macrophage/microglia and astrocyte morphology (anti-LCN2, brown, b) in chronic ischemic lesions.
LCN2 immunoreactivity is also found in neurons in peri-infarct areas at day 7 after tMCAO (anti-LCN2, brown;
anti-NeuN, green; c).
doi:10.1371/journal.pone.0154797.g002
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macrophages/microglia up to 42 days post tMCAO. Furthermore, we found neuronal
LCN2-immunoreactivity in peri-infarct areas up to 1 week post tMCAO. Previous studies
revealed a role of LCN2 in the migration of astrocytes, microglia and neurons by the induction
of chemokine expression [24–26], thereby suggesting favorable effects of LCN2 in post-stroke
remodeling. However, an association with the induction of astrogliosis and neuronal cell death
has also been reported [23,26,27]. The deposition of nonprotein-bound iron after transient
experimental ischemia as well as glial iron deposition 3–24 weeks after experimental ischemia
has been found previously [42–44]. LCN2 has been shown to contribute to iron homeostasis.
We observed an increase in the deposition of cellular nonheme iron in ischemic hemispheres
with a decrease of LCN2 expression in our animal model. Comparable amounts of LCN2 were
found in serum of tMCAO and control mice one week after ischemia. This suggests that a
release of a significant amount of LCN2 from the ischemic brain into the circulation is unlikely.
In this mouse model of tMCAO, all animals received preventive antibiotic treatment.
In ischemic stroke patients, higher plasma levels of LCN2 measured one week after stroke
correlated with worse clinical outcome at 90 days in our study. Increased levels of LCN2 were
associated with post-stroke infections and supposedly reflect the response of circulating neu-
trophils to infections. Neutrophils serve as a major reservoir of LCN2 [4–7]. The average life-
span of circulatory neutrophils is 5.4 days [45]. Therefore, the increase in peripheral LCN2
levels at one week after stroke rather derives from newly recruited neutrophils and not from a
response to the acute ischemia at the day of stroke onset.
The strength of our study is the exact timing with a predefined interval from stroke onset to
blood sampling to include information about changes of circulating LCN2 upon ongoing post-
stroke infections. Previous studies about blood biomarkers in stroke patients have not applied
such a strict criterion but rather lumped together sampling at the day of the acute incident and
sampling at several days afterwards. In previous studies, the different timing of blood sampling
has blurred a distinction whether interleukin-6 could serve as a marker of simultaneously evolv-
ing post-stroke infections or rather as their predictor [46]. In our study, with an interval of one
week from stroke onset to blood sampling, we could show that circulating LCN2 is a marker
of simultaneously evolving infections and contributes to the prediction of clinical outcome.
Fig 3. Quantification of lipocalin-2 positive cells (grey) and nonheme iron staining cells (black) in the
ischemic striatum in mice after temporal middle cerebral artery occlusion (tMCAO).Data are presented
as mean and standard error; *p<0.001 day 14 vs. days 1 and 7; **p<0.01 day 14 vs. day 7, p<0.001 day 14
vs. days 1, 28 and 42.
doi:10.1371/journal.pone.0154797.g003
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Fig 4. Immunohistochemistry in the mouse brain after temporal middle cerebral artery occlusion
(tMCAO). In adjacent serial sections at day 14 following tMCAO, cellular nonheme iron staining (a) co-
localizes with macrophage/microglia (b) but not with glial fibrillary acidic protein (GFAP) immunoreactivity (c).
doi:10.1371/journal.pone.0154797.g004
Lipocalin-2 in Ischemic Stroke
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Table 1. Demographic data and clinical characteristics of patients.
all patients mRS 0–2 mRS 3–6 p
n 46 13 33 -
median age; years (IQR) 71 (63–79) 68 (54–74) 76 (63–79) 0.107
female sex (n) 47.8% (22) 53.8% (7) 45.5% (15) 0.987
median NIHSS (IQR) 11 (6–17) 6 (5–8) 13 (7–18) 0.002
thrombolysis (n) 26.1% (12) 38.5% (5) 21.2% (7) 0.276
post-stroke infections (n) 58.7% (27) 23.1% (3) 72.7% (24) 0.006
mean eGFR (IQR) 75,6 ml/min/1.7 (85,4–65,7) 69,6 ml/min/1.7 (80,6–58,7) 77,9 ml/min/1.7 (89,0–66,8) 0.269
hypertension (n) 84.8% (39) 100% (13) 78.8% (26) 0.166
hypercholesterolemia(n) 47.8% (22) 61.5% (8) 42.4% (14) 0.400
diabetes mellitus (n) 21.7% (10) 23.1% (3) 21.2% (7) 1.000
atrial ﬁbrillation (n) 41.3% (19) 23.1% (3) 48.5% (16) 0.214
hemorrhagic transformation (n) 13.0% (6) 7.7% (1) 15.2% (5) 0.659
TACS (n) 41.3% (19) 7.7% (1) 54.5% (18) 0.010
PACS (n) 50.0% (23) 69.2% (9) 42.4% (14) 0.190
POCS (n) 4.3% (2) 15.4% (2) 0 0.075
LACS (n) 4.3% (2) 7.7% (1) 3.0% (1) 0.490
supra-aortic atherosclerosis (n) 21.7% (10) 7.7% (1) 27.3% (9) 0.240
cardio-aortic embolism (n) 52.2% (24) 46.2% (6) 54.5% (18) 0.853
small artery occlusion (n) 0 0 0 -
other uncommon stroke causes (n) 6.5% (3) 7.7% (1) 6.1% (2) 1.000
undetermined stroke causes (n) 19.6% (9) 38.5% (5) 12.1% (4) 0.092
IQR, interquartile range; NIHSS, National Institutes of Stroke Scale; eGFR, estimated glomerular ﬁltration rate; TACS, total anterior circulation syndrome;
PACS, partial anterior circulation syndrome; POCS, posterior circulation syndrome; LACS, lacunar syndrome
doi:10.1371/journal.pone.0154797.t001
Fig 5. Plasma levels of lipocalin-2 in patients obtained at a median of 7 (range 5–9) days after
ischemic stroke onset. First, patients were dichotomized into favourable (mRS 0–2) and unfavourable
(mRS 3–6) outcomes assessed 90 days after stroke. Second, patients were dichotomized if they had
developed post-stroke infections or not. Plots display the median, interquartile range (box), 10th and 90th
percentiles (whiskers); *p<0.05; **p<0.01. Abbreviation: mRS = modified Rankin Scale
doi:10.1371/journal.pone.0154797.g005
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Although our study cohort is selected, with our exclusion criteria we intended to exclude factors
other than post-stroke infections which could have an influence on circulating LCN2.
Conclusion
A wide range of biomarkers has been evaluated for their relevance as predictors of clinical out-
come after ischemic stroke [46–49]. However, no infection-related serum/plasma biomarker is
currently applied in clinical routine. Our study shows that LCN2, measured in peripheral
blood one week after stroke onset, is an infection-related biomarker related to the clinical out-
come at 90 days. Although LCN2 is expressed in the ischemic brain, peripherally circulating
LCN2 is not a marker of brain damage. Biomarkers in peripheral blood which could improve
diagnosis and treatment of post-stroke infections are needed. Therefore, large multicenter
efforts should aim to replicate the findings of this study.
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